Primary Hyperoxaluria Clinical Trial
Official title:
Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network
NCT number | NCT02026388 |
Other study ID # | 11-005413 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 2013 |
Est. completion date | June 2025 |
Verified date | July 2023 |
Source | Mayo Clinic |
Contact | Barb M Seide |
Phone | 507-255-0387 |
seide.barbara[@]mayo.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | June 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria: 1. Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below the normal reference range confirming PH type 1 OR Liver biopsy documenting glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal reference range confirming PH type 2 2. Molecular genetic analysis (DNA testing) confirming mutations known to cause PH type 1, PH type 2, or PH type 3 3. Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (>70 mg/1.73 m2/day) in the absence of a identifiable causes of secondary hyperoxaluria, including gastrointestinal disease known to cause enteric hyperoxaluria 4. A patient in end stage kidney failure, in whom neither a liver biopsy nor mutational analysis are available must have: (a) A plasma oxalate concentration of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate deposits OR (b) Evidence of systemic oxalosis 5. Participants in the previous protocol "Tissue Bank of Urine, Blood, and Tissue Samples Collected from the Patients with Primary Hyperoxaluria" 'Mayo IRB #' #80-04. They have already consented to bank their samples and that consent will serve to enroll them in this study. - Diagnosis of Dent disease meeting one or more of the following criteria: 1. Identified mutation of the gene that encodes for chloride exchange transporter 5 (CLCN5) 2. Low molecular weight proteinuria and hypercalciuria 3. Low molecular weight proteinuria and nephrocalcinosis - Diagnosis of APRT disease meeting one or more of the following criteria: 1. Suspected dihydroxyadeninuria and absent APRT enzyme activity measured in red blood cells (RBCs). 2. Homozygosity, or compound heterozygosity, for known disease-causing APRT mutations. 3. Passage of dihydroxyadenine stones (confirmed with stone analysis). - Diagnosis of Cystinuria meeting one or more of the following criteria: 1. Stone analysis demonstrating that the stone contains cystine 2. Increased urinary cystine excretion (>250 mg/gm creatinine) - Relative of someone with confirmed primary hyperoxaluria, Dent disease, APRT deficiency (also known as dihydroxyadeninuria), or cystinuria Exclusion Criteria: 1. Stone formers who do not meet the inclusion criteria for primary hyperoxaluria, cystinuria, Dent disease, or APRT deficiency. 2. Unwilling or unable to provide consent/assent. |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of samples stored in tissue bank | encourage more research | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00875823 -
International Registry for Primary Hyperoxaluria
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT02340689 -
Primary Hyperoxaluria Mutation Genotyping/Phenotyping
|
||
Completed |
NCT00638703 -
Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT03819647 -
Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
|
Phase 2 | |
Completed |
NCT02000219 -
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis
|
Phase 2 | |
Recruiting |
NCT05843851 -
Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria
|
N/A | |
Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
Completed |
NCT03391804 -
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
|
Phase 2 | |
Completed |
NCT03116685 -
A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
|
Phase 3 | |
Recruiting |
NCT05107830 -
Phenotyping of Primary Hyperoxaluria
|
||
Active, not recruiting |
NCT04152200 -
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
|
Phase 3 | |
Recruiting |
NCT05001269 -
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
|
Phase 2 | |
Completed |
NCT03392896 -
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
|
Phase 1 | |
Completed |
NCT02012985 -
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria
|
Phase 1/Phase 2 | |
Completed |
NCT01037231 -
Phase 2/3 Oxabact Study
|
Phase 2/Phase 3 | |
Completed |
NCT00589225 -
Primary Hyperoxaluria Mutation Genotyping
|
Phase 1 | |
Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
Completed |
NCT03350451 -
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
|
Phase 2 |